BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced on January 13, 2026 that it awarded an inducement grant on January 10, 2026 under its 2025 Inducement Plan to an individual hired in December 2025.

The grant comprises non-qualified stock options to purchase 129,090 shares of common stock at an exercise price of $13.19 per share (the Nasdaq closing price on the grant date). The options vest 25% on the first anniversary of the employee’s start date and then in 36 equal monthly installments, subject to continued service. The 2025 Inducement Plan was adopted by the board in October 2025, and the awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

+4.60% 1.7x vol

18 alerts

+4.60% News Effect

-5.0% Trough in 1 hr 31 min

+$41M Valuation Impact

$941M Market Cap

1.7x Rel. Volume

On the day this news was published, BBOT gained 4.60%, reflecting a moderate positive market reaction. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $41M to the company's valuation, bringing the market cap to $941M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options granted: 129,090 shares Exercise price: $13.19 per share Par value: $0.0001 per share +3 more

6 metrics

Inducement options granted 129,090 shares Non-qualified stock options under 2025 Inducement Plan

Exercise price $13.19 per share Closing price on January 10, 2026 grant date

Par value $0.0001 per share BBOT common stock par value

Initial vesting 25% after 1 year Cliff vesting on first anniversary of start date

Remaining vesting schedule 36 monthly installments After first anniversary, subject to continued service

Nasdaq rule reference Rule 5635(c)(4) Basis for inducement grant exemption

Market Reality Check

Price: $11.41 Vol: Volume 437,489 is about 1...

normal vol

$11.41 Last Close

Volume Volume 437,489 is about 1.4x the 20-day average of 311,823, showing elevated trading ahead of this HR-related news. normal

Technical Shares at $12.67 are trading above the 200-day MA of $11.55 and about 14.8% below the 52-week high of $14.87.

Peers on Argus

BBOT fell about 3.9% while peers showed mixed moves: GERN +5.93%, IVA +5.42%, AV...

BBOT fell about 3.9% while peers showed mixed moves: GERN +5.93%, IVA +5.42%, AVXL -0.23%, IMNM -1.91%, PRAX -2.57%. This points to stock-specific trading rather than a uniform biotech move.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Clinical data update	Positive	+4.4%	Preliminary Phase 1 safety and antitumor data across three RAS/PI3Kα programs.
Dec 16	Conference presentation	Positive	-1.3%	Notice of J.P. Morgan Healthcare Conference presentation and webcast availability.
Dec 11	Inducement grant	Neutral	-1.9%	Stock option inducement grant for a new hire under the 2025 Inducement Plan.
Dec 10	Preclinical data	Positive	+2.8%	Late-breaking preclinical data on BBO-10203 as a first-in-class RAS:PI3Kα breaker.
Nov 18	Investor conferences	Neutral	-1.8%	Participation in multiple December healthcare investor conferences with webcast access.

Pattern Detected

BBOT has tended to trade higher on positive RAS/PI3K data updates, while corporate or administrative news (conferences, inducement grants) often coincided with modest declines.

Recent Company History

Over the last few months, BBOT has highlighted advancing RAS and PI3Kα programs and stepped up investor outreach. On Jan 7, 2026, preliminary Phase 1 data across three oral programs drove a 4.36% gain. Preclinical data on BBO-10203 at SABCS on Dec 10, 2025 also saw a positive reaction of 2.79%. In contrast, conference participation announcements in November–December 2025 and a prior inducement grant on Dec 10, 2025 were followed by small negative moves, similar in nature to today’s HR-focused option award.

Market Pulse Summary

This announcement details a standard inducement stock option grant of 129,090 shares at an exercise ...

Analysis

This announcement details a standard inducement stock option grant of 129,090 shares at an exercise price of $13.19 under BBOT’s 2025 Inducement Plan, structured to comply with Nasdaq Listing Rule 5635(c)(4). Historically, similar HR or administrative items, such as the prior December 2025 inducement grant, have had less impact than clinical and preclinical RAS/PI3Kα updates. Investors following BBOT may focus more on upcoming trial data and program milestones than on routine equity awards when assessing the company’s trajectory.

Key Terms

non-qualified stock options, exercise price, Nasdaq Listing Rule 5635(c)(4), inducement grant

4 terms

non-qualified stock options financial

"The employee received non-qualified stock options to purchase 129,090 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"...with an exercise price of $13.19 per share, the closing price of BBOT’s common stock..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rule 5635(c)(4) regulatory

"...as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grant financial

"...announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan..."

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025.

The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $13.19 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

What did BridgeBio Oncology Therapeutics (BBOT) announce on January 13, 2026?

BBOT announced an inducement grant awarded January 10, 2026 of non-qualified stock options to a new employee hired in December 2025.

How many shares and what exercise price were included in the BBOT inducement grant?

The grant covers options to purchase 129,090 shares with an exercise price of $13.19 per share.

What is the vesting schedule for the BBOT options granted under the 2025 Inducement Plan?

The options vest 25% on the first anniversary of the employee’s start date and then in 36 equal monthly installments thereafter, subject to continued service.

When was BBOT's 2025 Inducement Plan adopted and who approved the awards?

The board adopted the 2025 Inducement Plan in October 2025, and the compensation committee approved the awards as a material inducement under Nasdaq Listing Rule 5635(c)(4).

Does the announced grant affect BBOT shareholders immediately?

The announcement grants options that may dilute shares if exercised in the future, but no immediate share issuance was reported in the announcement.

Why were the awards granted outside BBOT’s stockholder-approved equity plans?

The awards were granted as material inducement grants under the company’s separate 2025 Inducement Plan for a newly hired employee, consistent with Nasdaq Listing Rule 5635(c)(4).